BR9911383A - Cdna de paramyxovirus de ave, rna, processo para gerar cópia infecciosa do paramyxovirus de ave e para distinguir animais não vacinados ou animais vacinados com uma vacina do ndv, cópia infecciosa do paramyxovirus de ave, vacina, e, conjunto de diagnóstico. - Google Patents

Cdna de paramyxovirus de ave, rna, processo para gerar cópia infecciosa do paramyxovirus de ave e para distinguir animais não vacinados ou animais vacinados com uma vacina do ndv, cópia infecciosa do paramyxovirus de ave, vacina, e, conjunto de diagnóstico.

Info

Publication number
BR9911383A
BR9911383A BR9911383-0A BR9911383A BR9911383A BR 9911383 A BR9911383 A BR 9911383A BR 9911383 A BR9911383 A BR 9911383A BR 9911383 A BR9911383 A BR 9911383A
Authority
BR
Brazil
Prior art keywords
ndv
paramyxovirus
vaccine
animals
bird
Prior art date
Application number
BR9911383-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernardus Petrus Huber Peeters
Olav Sven De Leeuw
Guus Koch
Arnoud Leonard Josef Gielkens
Original Assignee
Id Lelystad Inst Dierhouderij
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9911383(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Id Lelystad Inst Dierhouderij filed Critical Id Lelystad Inst Dierhouderij
Publication of BR9911383A publication Critical patent/BR9911383A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9911383-0A 1998-06-19 1999-06-17 Cdna de paramyxovirus de ave, rna, processo para gerar cópia infecciosa do paramyxovirus de ave e para distinguir animais não vacinados ou animais vacinados com uma vacina do ndv, cópia infecciosa do paramyxovirus de ave, vacina, e, conjunto de diagnóstico. BR9911383A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202054A EP0974660A1 (en) 1998-06-19 1998-06-19 Newcastle disease virus infectious clones, vaccines and diagnostic assays
PCT/NL1999/000377 WO1999066045A1 (en) 1998-06-19 1999-06-17 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Publications (1)

Publication Number Publication Date
BR9911383A true BR9911383A (pt) 2001-03-13

Family

ID=8233832

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911383-0A BR9911383A (pt) 1998-06-19 1999-06-17 Cdna de paramyxovirus de ave, rna, processo para gerar cópia infecciosa do paramyxovirus de ave e para distinguir animais não vacinados ou animais vacinados com uma vacina do ndv, cópia infecciosa do paramyxovirus de ave, vacina, e, conjunto de diagnóstico.

Country Status (28)

Country Link
US (3) US6719979B2 (enExample)
EP (2) EP0974660A1 (enExample)
JP (3) JP2002518012A (enExample)
KR (1) KR20010053000A (enExample)
CN (2) CN101275142A (enExample)
AR (1) AR020091A1 (enExample)
AT (1) ATE367442T1 (enExample)
AU (1) AU754844B2 (enExample)
BR (1) BR9911383A (enExample)
CA (1) CA2334165A1 (enExample)
CZ (1) CZ300760B6 (enExample)
DE (1) DE69936585T2 (enExample)
DK (1) DK1088077T3 (enExample)
EA (1) EA004796B1 (enExample)
ES (1) ES2291029T3 (enExample)
HR (1) HRP20010042B1 (enExample)
HU (1) HUP0102429A3 (enExample)
ID (1) ID27343A (enExample)
IL (2) IL140381A0 (enExample)
NO (1) NO329193B1 (enExample)
NZ (1) NZ508982A (enExample)
PL (1) PL197722B1 (enExample)
PT (1) PT1088077E (enExample)
SI (1) SI1088077T1 (enExample)
TR (1) TR200100350T2 (enExample)
UA (1) UA77146C2 (enExample)
WO (1) WO1999066045A1 (enExample)
ZA (1) ZA200100241B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
AU4971500A (en) * 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
EP1074614B1 (en) * 1999-07-27 2004-07-07 Akzo Nobel N.V. A recombinant Newcastle disease virus for in ovo vaccination
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
AU2001263896A1 (en) 2000-06-23 2002-01-14 Akzo Nobel N.V. Attenuated bovine respiratory syncytial virus
WO2002036617A2 (en) * 2000-11-02 2002-05-10 Akzo Nobel N.V. A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
KR100437888B1 (ko) * 2001-07-30 2004-07-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
ATE307606T1 (de) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
EP1485488A4 (en) * 2002-02-21 2005-03-02 Sinai School Medicine RECOMBINANT EXPRESSION SYSTEMS FOR MINUSTRAN VIRUS RNA AND VACCINES
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
KR20060035596A (ko) 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
KR20060029214A (ko) * 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US7527638B2 (en) 2003-12-16 2009-05-05 Depuy Spine, Inc. Methods and devices for minimally invasive spinal fixation element placement
MY146476A (en) 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
JP5603012B2 (ja) * 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
KR20090007706A (ko) * 2006-03-15 2009-01-20 인터벳 인터내셔널 비.브이. 조류 인플루엔자 바이러스의 ｈ5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스
AU2007226555B2 (en) * 2006-03-15 2012-07-05 Intervet International B.V. Recombinant Mononegaviral virus vectors
KR100776398B1 (ko) * 2006-03-23 2007-11-28 주식회사 고려비엔피 조류 ｈｎ 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
KR100955502B1 (ko) * 2007-11-30 2010-04-30 대한민국 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
US20090258035A1 (en) * 2008-03-21 2009-10-15 The United States Of America, As Represented By The Secretary Of Agriculture Avian virus vaccines and uses thereof
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
KR101745029B1 (ko) * 2009-08-21 2017-06-08 메리얼 인코포레이티드 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
HRP20190525T4 (hr) 2011-11-30 2023-01-20 Boehringer Ingelheim Animal Health USA Inc. Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
CN104059942B (zh) * 2013-03-20 2016-12-28 湖北省农业科学院畜牧兽医研究所 新城疫病毒耐热活疫苗载体系统及其应用
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
US10780158B2 (en) 2015-11-16 2020-09-22 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
SG10202108573TA (en) 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2019227531B2 (en) * 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
CA3106170A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN109735552A (zh) * 2019-02-27 2019-05-10 苏州世诺生物技术有限公司 禽新城疫病毒新型基因工程亚单位疫苗
CN110018304A (zh) * 2019-05-15 2019-07-16 河南省农业科学院 一种新城疫抗体阻断检测试纸
CN110240635B (zh) * 2019-06-10 2022-04-22 华中农业大学 检测新城疫病毒抗体的多肽及其elisa检测试剂盒
CN110257562A (zh) * 2019-07-31 2019-09-20 河北农业大学 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用
US11334671B2 (en) * 2019-10-14 2022-05-17 International Business Machines Corporation Adding adversarial robustness to trained machine learning models
KR102154796B1 (ko) * 2019-10-18 2020-09-22 주식회사 바이오포아 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
CN110938711A (zh) * 2019-12-20 2020-03-31 河北农业大学 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法
CN111334528B (zh) * 2020-03-20 2022-02-18 山东农业大学 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN112048484A (zh) * 2020-07-27 2020-12-08 华南农业大学 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114214338B (zh) * 2021-08-26 2023-02-03 扬州大学 猪源piv5全长感染性克隆及其制备方法和应用
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体
WO2026072752A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996040880A1 (en) * 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
EP0780475B2 (en) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines

Also Published As

Publication number Publication date
WO1999066045A1 (en) 1999-12-23
EP1088077B2 (en) 2012-03-21
SI1088077T1 (sl) 2008-02-29
JP2006141398A (ja) 2006-06-08
CZ300760B6 (cs) 2009-08-05
HUP0102429A3 (en) 2003-12-29
AU754844B2 (en) 2002-11-28
IL140381A (en) 2008-06-05
TR200100350T2 (tr) 2001-06-21
DE69936585T2 (de) 2008-04-30
PL348300A1 (en) 2002-05-20
EP0974660A1 (en) 2000-01-26
NO20006406D0 (no) 2000-12-15
CN1314942A (zh) 2001-09-26
AU4399199A (en) 2000-01-05
NZ508982A (en) 2003-07-25
NO329193B1 (no) 2010-09-13
DK1088077T3 (da) 2007-11-12
KR20010053000A (ko) 2001-06-25
UA77146C2 (en) 2006-11-15
US6719979B2 (en) 2004-04-13
IL140381A0 (en) 2002-02-10
ZA200100241B (en) 2002-06-26
HUP0102429A2 (hu) 2001-10-28
ATE367442T1 (de) 2007-08-15
EA004796B1 (ru) 2004-08-26
US20040234552A1 (en) 2004-11-25
CA2334165A1 (en) 1999-12-23
HRP20010042B1 (en) 2011-03-31
ID27343A (id) 2001-04-05
US7547442B2 (en) 2009-06-16
DE69936585D1 (de) 2007-08-30
HRP20010042A2 (en) 2001-12-31
NO20006406L (no) 2001-02-19
ES2291029T3 (es) 2008-02-16
EA200100057A1 (ru) 2001-08-27
JP2002518012A (ja) 2002-06-25
JP2009261387A (ja) 2009-11-12
AR020091A1 (es) 2002-04-10
US20030087417A1 (en) 2003-05-08
CN101275142A (zh) 2008-10-01
PT1088077E (pt) 2007-10-29
CZ20004707A3 (en) 2001-05-16
EP1088077A1 (en) 2001-04-04
US20040235134A1 (en) 2004-11-25
EP1088077B1 (en) 2007-07-18
US7332169B2 (en) 2008-02-19
PL197722B1 (pl) 2008-04-30

Similar Documents

Publication Publication Date Title
AR020091A1 (es) Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y
CY1106493T1 (el) Μεταλλαγμενη μορφη νουκλεοπρωτεϊνης ανασυνδυασμενου ιου ασθενειας του newcastle ως εμβολιο δεικτης
PT835930E (pt) Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
HUP9903822A2 (hu) Polinukleotid-vakcinakészítmény sertések szaporodásbiológiai és légzőszervi kórképei ellen
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
ES2001752A6 (es) Procedimiento para producir una vacuna de herpesvirus, y para produciruna vacuna multivalente.
NO902802D0 (no) Kimaere glykoproteiner inneholdende immunogene segmenter av glykoproteinene fra human respiratorisk syncytielt virus.
Abdel-Alim et al. Immunogenicity and antigenicity of very virulent strains of infectious bursal disease viruses
Jackwood et al. Attenuation, safety, and efficacy of an infectious bronchitis virus GA98 serotype vaccine
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
BR9713254A (pt) Vacina viva contra helicobacter pylori
BR0102322A (pt) Vìrus de uma cepa de vìrus de doença bursal infecciosa, vacina contra doença bursal infecciosa, métodos para a preparação do vìrus, e da vacina, e, uso do vìrus
Hunter et al. A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep
ES2053477T3 (es) Vacuna viva para enfermedades contagiosas de pollos.
HUP9702355A2 (hu) Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
DE68920345D1 (de) Lebendes Kombinationsvakzin.
RU2078817C1 (ru) Аттенурованный холодоадаптированный штамм вируса гриппа, используемый для получения живой интраназальной гриппозной вакцины
BR0212279A (pt) Vacina obtida de linhagem celular para vìrus causador de anemia em galinhas
Kimura Immuno-electron microscopic study on the antigenicity of tubular structures associated with human rotavirus
BR0100695A (pt) Vìrus de anemia de galinhas (cav), processo a preparação deste, vacina para a proteção de aves domésticas contra estados de doença resultantes de uma infecção por cav, processo para a preparação da mesma, uso de um cav, e, processo para o controle de estados de doença que resultam de uma infecção por cav em aves domésticas
Ubaydullo o’g et al. VIRAL DISEASES OF THE RESPIRATORY SYSTEM
Ebrahimi et al. Clone Purification, characterization and standardization of Lasota strain for developing a live vaccine against Newcastle disease virus
SU1036739A1 (ru) Штамм 47/7/2 вируса гриппа @ ( @ ),используемый дл получени живой интраназальной вакцины дл детей

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK (NL)

Free format text: TRANSFERIDO DE: ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2223 DE 13/08/2013.